Licensing & Acquisition Opportunities

Large pharma and biotech companies are in an environment of increased M&A activity, with catalysts including a need to replace revenue from drugs losing patent protection, excess cash, and ineffective internal pipelines. The threat of a shift in pricing regulation adds more uncertainty to the landscape. Given this backdrop, there has never been more of a need to engage with an agnostic partner to provide objective third-party input to support your efforts.

inThought works with business development groups such as yours, providing idea generation and due diligence analyses. In addition to deep subject matter expertise in multiple therapeutic areas, many of our principals have a Wall Street background and are comfortable with providing quick, bespoke assessments of an indication, company, or specific program.

  • M&A Idea Generation. We can help you survey the current landscape to make key merger and acquisition decisions.
  • Company Profiling. We can provide a thorough assessment of company assets, structure, technology, processes, and key parties.
  • Revenue Modeling. Leverage informed revenue forecasting models so you can make important business decisions with confidence. Learn more.
  • Probability of Approval Assessments. Our dynamic approval forecasts factor in historical approval rates, current market progress and other pertinent data. Learn more.
  • KOL Primary Research. Track trends stemming from key opinion leaders, and use our expert analysis to test your strategies. Learn more.
  • Other Ad Hoc Requests. We offer custom consulting solutions. Let us know what you need, and we can work out a plan of action. Learn more.
 

Grow Your Business

inThought is your dedicated partner throughout the drug development process and beyond. Contact us today for the support you need to fully understand, monitor, and monetize the opportunities and threats that will shape your business.

inThought Research empowers biopharma leaders with comprehensive strategic insights. We combine Wall Street financial acumen and swiftness, scientific expertise, and advanced AI analytics to navigate the complex landscape of drug development.

Linkedin
Quick Links
Get In Touch
Our Family Of Companies​
inThought Labs logo

Privacy Policy

Terms of Service

Services

Vulnerability

© 2024 inThought Research. All Rights Reserved.

Contact us

Learn how inThought Labs can simplify your life and empower your team with expert consultants and our cloud-based system, inVision.

Chris Martin

President

As the president of inThought Labs, Chris is focused on constantly improving inVision, the leading competitive and market intelligence platform for the biopharmaceutical industry, to better meet the changing needs of clients.

 

With 20 years of experience in roles being a consumer of market and competitive information, Chris understands the needs and priorities of clients. Chris was a senior principal and co-founder of inThought, a life science consulting, market research, and analytics firm. Collaborating with Ben Weintraub, Chris also co-founded BiotechTracker, an online tool for investors and precursor to inVision. Previous to inThought, he was a healthcare analyst and co-portfolio manager at two investment firms. Chris served in health care policy roles at the White House Office of Management and Budget. These roles included Medicare Desk Officer at the Office of Information and Regulatory Affairs, where he was responsible for providing recommendations to senior White House policy officials on healthcare policies and regulations.

 

Chris has a Master in Business Administration from Harvard Business School, a Master in Engineering from Villanova University, and a Bachelor of Science in Engineering from Cornell University. Prior to attending Harvard Business School, Chris served on two U.S. Navy nuclear submarines and at the Pentagon.